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Abstract
For the treatment of metastatic renal cell cancer several strategies are used among which the mTOR inhibitor everolimus. As 
mTOR plays an important role in the immune system, e.g., by controlling the expression of the transcription factor FoxP3 
thereby regulating regulatory T cells (Tregs), it plays a key role in the balance between tolerance and inflammation. Previous 
reports showed stimulatory effects of mTOR inhibition on the expansion of Tregs, an effect that can be considered detrimental 
in terms of cancer control. Since metronomic cyclophosphamide (CTX) was shown to selectively deplete Tregs, a phase 1 
clinical trial was conducted to comprehensively investigate the immune-modulating effects of several dosages and schedules 
of CTX in combination with the standard dose of everolimus, with the explicit aim to achieve selective Treg depletion. Our 
data show that 50 mg of CTX once daily and continuously administered, in combination with the standard dose of 10 mg 
everolimus once daily, not only results in depletion of Tregs, but also leads to a reduction in MDSC, a sustained level of 
the  CD8+ T-cell population accompanied by an increased effector to suppressor ratio, and reversal of negative effects on 
three peripheral blood DC subsets. These positive effects on the immune response may contribute to improved survival, and 
therefore this combination therapy is further evaluated in a phase II clinical trial.
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Introduction
Kidney cancer is one of the ten most common cancer 
types in both men and women, with an estimated num-
ber of 338,000 new cases per year [1]. The most com-
mon tumor arising in the kidney is renal cell carcinoma 
(RCC) and a total of more than ten different subtypes can 
be identified [2]. The therapeutic field of metastatic RCC 
(mRCC) has drastically changed in the past decade with 
the introduction of the VEGF signaling pathway inhibitors 
and inhibitors of mammalian target of rapamycin (mTOR) 
[3]. For years, everolimus has been the standard second-
line treatment after a VEGF-based treatment regimen 
until the arrival of axitinib as an alternative and recently 
nivolumab and cabozantinib, drugs that inhibit the PD-1 
immune checkpoint and the MET, AXL and VEGF tyro-
sine kinases, were shown to be more effective compared 
to everolimus [4–6]. Furthermore, the progression-free 
survival (PFS) of patients with mRCC was improved by 
addition of the multi-target tyrosine kinase inhibitor len-
vatinib to everolimus [7].
Everolimus has been shown to be an effective inhibitor 
of mTOR, resulting in inhibition of cell growth, prolifera-
tion, angiogenesis and survival of tumor cells [8]. How-
ever, mTOR also plays an important role in the regula-
tion of the immune response, by promoting the expansion 
of regulatory T cells (Tregs) [9, 10]. Since Tregs have 
immune suppressive capacities, this Treg-promoting effect 
of everolimus can be considered a detrimental effect in the 
treatment of cancer. In support of this notion, increased 
Treg numbers have been associated with poor survival in 
patients with cancer, including mRCC [11–13].
Several strategies have been investigated to selectively 
deplete Tregs, among them the use of low-dose cyclophos-
phamide (CTX). Administration of metronomic low-dose 
CTX was reported to selectively deplete Tregs, with addi-
tional beneficial effects on T and NK cell functionality 
[14, 15]. Therefore, a phase 1 clinical trial was initiated 
to prevent everolimus-induced detrimental Treg expan-
sion, by adding metronomic CTX to the standard dosage 
of everolimus [16], to achieve improved survival by modu-
lating the immune system. Patients were treated in cohorts 
of five patients, with six different doses and schedules of 
CTX. Clinical results and results of changes in Treg fre-
quencies in the various cohorts of this phase 1 trial were 
separately described [17]. Here, we report on the results of 
the extensive and comprehensive immune monitoring that 
was additionally performed in this phase 1 study, where 
patients were treated with either everolimus alone or the 
combination of everolimus and different CTX administra-
tion dosages and schedules.
Materials and methods
Study population
Forty patients with mRCC and previously treated with a 
VEGF targeting regimen were treated with everolimus in 
combination with different doses and schedules of met-
ronomic oral CTX. Thirty-nine patients were evaluable, 
since one patient was not able to complete 2 weeks of the 
treatment due to early toxicity. The trial was initiated by 
the department of medical oncology of the Amsterdam 
UMC, location VUmc and conducted within the context 
of the Netherlands Working Group on Immunotherapy of 
Oncology (WIN-O) with participation of 13 hospitals and 
enrollment of patients from January 2012 until August 2015. 
Clinical findings were reported separately [17].
Treatment
Patients were treated with a fixed dose of 10 mg everoli-
mus once daily and enrolled in one of the seven cohorts, 
five patients per cohort, with different doses and schedules 
of low-dose oral CTX. One patient in dose level 6 stopped 
treatment because of several toxicities (highest grade 3 nau-
sea) within 2 weeks of enrollment and was not evaluable. 
CTX was scheduled week on/week off or continuously, once 
or twice daily, based on the previously used dose regimens 
reported by Ghiringhelli et al. [15]. In cohort 0, patients 
were treated with 10 mg everolimus without CTX. In cohort 
1, patients were treated with everolimus and 50 mg CTX 
once daily, week on/week off. In cohort 2, patients were 
treated with everolimus and 50 mg CTX once daily in a 
continuous scheme. In cohort 3, patients received 50 mg 
CTX twice daily, week on/week off, and in cohort 4 patients 
received 50 mg CTX twice daily, continuously. In the last 
two cohorts, cohort 5 and 6, respectively, patients received 
100 mg CTX twice daily, in cohort 5 in a week on/week off 
regimen and in cohort 6 continuously.
Immune monitoring
At baseline and after 2, 4, and 8 weeks after the start of study 
treatment, 60 mL of heparinized peripheral blood was col-
lected for immune monitoring. All materials were processed 
on the same day the blood was drawn. PBMC were isolated 
by density-gradient centrifugation with Lymphoprep (Axis-
Shield, Oslo, Norway). After isolation, PBMC were stored 
overnight at 4 °C in RPMI 1640 (Lonza, Basel, Switzerland) 
supplemented with 100 IU/ml sodium penicillin (Astellas 
Pharma, Leiden, the Netherlands), 100 mg/ml streptomycin 
sulfate (Radiumfarma-Fisiofarma, Naples, Italy), 2.0 nM 
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L-glutamine (Life Technologies, Bleiswijk, the Nether-
lands), 10% FBS (HyClone, Amsterdam, the Netherlands), 
and 0.05 mM 2-ME (Merck, Darmstadt, Germany). The next 
day, cells were stained for flow cytometric analysis.
Flow cytometry
FITC, PE, PerCP or allophycocyanin (APC)-labeled anti-
bodies directed against human CD3, CD4, CD8, CD11c, 
CD14, CD16, CD19, CD25, CD56, CD86, CD123, CTLA-4, 
HLA-DR, Ki-67, PD-1, (all BD Biosciences, New Jersey, 
USA), CD33, (Beckman Coulter Inc., California, USA), 
CD56 (IQ Products, Groningen, the Netherlands), and blood 
DC antigens BDCA1, BDCA2, BDCA3 (all from Miltenyi 
Biotec, Bergisch-Gladbach, Germany) and matching isotype 
control antibodies were used. Stainings were performed in 
PBS supplemented with 0.1% BSA and 0.02% sodium azide 
for 30 min. Intracellular staining was performed after fixa-
tion and permeabilization using a fixation/permeabilization 
kit according to the manufacturer’s protocol (eBioscience). 
For staining of FoxP3, a PE-labeled Ab against FoxP3 (clone 
PCH101, eBioscience) or AlexaFLuor488 FoxP3 (clone 
259D) (Biolegend) was used. Live cells were gated based on 
forward and side scatter and analyzed on a BD FACSCali-
bur (BD Biosciences) and analyzed using Kaluza Analysis 
Software (Beckman Coulter).
Statistical analysis
One-way repeated measures ANOVA was used to determine 
the statistical significance of differences within cohorts with 
Dunnett’s multiple comparison test as post-test. Two-way 
ANOVA was used to compare the mean values between 
cohorts. Differences were considered statistically signifi-
cant when p values were ≤ 0.05, as indicated with asterisks 
(*p ≤ 0.05, **p < 0.01, ***p < 0.001). Statistical analyses 
were performed using GraphPad Prism software (version 
7, 2016).
Results
The addition of a once daily oral dose of 50 mg 
CTX to treatment with everolimus results in Treg 
depletion and an increase in the  CD8+ T cell: Treg 
ratio without changes in T‑cell activation
As previously reported [16], the main objective of this 
trial was to determine the optimal dose and schedule of 
orally administered CTX, when combined with 10 mg 
everolimus, to obtain selective Treg depletion. As shown 
in Fig. 1a (left graphs), cohort 2, the cohort where 10 mg 
everolimus was combined with 50 mg CTX continuously, 
showed a significant decrease in Treg percentages (within 
 CD4+ T cells), both within the cohort, comparing the per-
centages at time point 0 to time point 4, and compared to 
the corresponding time point 4 in cohort 0, the everolimus 
only cohort, whereas  CD4+ T-cell percentages remained 
stable (Fig. 1a and Supplementary Table 1). Cohort 2 was 
the only cohort in which this effect was observed. Except 
for cohort 4, in which a significant decrease in  CD8+ T 
cells was observed in comparison to cohort 0 at time point 
4, no major differences were observed between cohorts 
in  CD8+ T-cell frequencies. On the other hand, the ratio 
of  CD8+ T cells to Tregs was significantly increased in 
cohort 2 compared to cohort 0 at week 4 (Fig. 1a). This 
increase in  CD8+ T cell:Treg ratio was only statistically 
significant in cohort 2. Based on the Treg-depleting data in 
cohort 2 and the observation that the Treg-depleting effect 
of CTX was less pronounced in subsequent cohorts, with 
even an increase in Treg percentages in cohort 5 and 6 (see 
Fig. 1a), the decision was made to proceed to the expan-
sion cohort wherein an additional 5 patients were treated 
with the combination of 10 mg everolimus and 50 mg CTX 
continuously (as in cohort 2). The expansion cohort again 
showed a significant decrease in Treg percentages at time 
point 4 in comparison to Treg percentages from cohort 0 
and a significant increase in the  CD8+ T cell:Treg ratio, 
thereby confirming the previously observed results of 
cohort 2 (Fig. 1b).
For T-cell activation, PD-1 and CTLA-4 expression was 
determined on  CD4+ and  CD8+ T cells. Overall, no consist-
ent or persistent changes in either PD-1 or CTLA-4 expres-
sion on either subset of T cells could be observed (Supple-
mentary Fig. 1a). This was also the case for cohort 2 and the 
expansion cohort 2E (Supplementary Fig. 1b). As Supple-
mentary Fig. 1 shows relative values, absolute percentages 
of PD-1 and CTLA-4 expression on  CD4+ and  CD8+ T cells 
are shown in supplementary table 2.
As a measure of the proliferative activity of Tregs and 
 CD4+ T cells, Ki-67 expression was determined in both 
cell types. As shown in Supplementary Fig. 2, a significant 
decrease in Treg Ki-67 expression was observed within 
cohort 3 and 5 comparing the expression at baseline to 
time point 2. In addition, the percentage of Ki-67+ Tregs 
in cohort 5 was significantly increased compared to cohort 
0 at week 4 (Supplementary Fig. 2a, left panels) and a sim-
ilar trend (not significant) was observed in cohort 6. For 
the  CD4+ T cells, a significantly lower percentage of cells 
expressed Ki-67 at week 2 in cohort 2 as compared to week 
0 (p < 0.001). Although not significant, an increase in  CD4+ 
T cells expressing Ki-67 was seen at time point 4 for cohort 
2 and subsequent cohorts showed a similar increase at time 
point 4, with a significant effect in cohort 6.
The results of the expansion cohort 2E (Supplementary 
Fig. 2b) were similar to cohort 2, however, the Ki-67+ Tregs 
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Fig. 1  Effect of different dosages and administration schedules 
of CTX when combined with a fixed dose of 10  mg everolimus on 
the frequency of Tregs,  CD8+ T cells, the effector to suppressor 
(CD8:Treg) ratio and  CD4+ T cells. a Relative percentages (to start) 
of Tregs,  CD8+ T cells, the effector to suppressor ratio and  CD4+ T 
cells were determined in freshly isolated PBMC from patients treated 
with different dosages and schedules of CTX, combined with a fixed 
dose of everolimus at baseline and subsequently 2, 4, and 8  weeks 
after start of treatment. Cohorts 1–6 correspond to the different CTX 
dosages and schedules investigated (black bullets, black line) and are 
compared to cohort 0, the everolimus only cohort (open bullet, dotted 
line). Tregs were determined within  CD4+ T cells,  CD8+ T cells and 
 CD4+ T cells within  CD3+ T cells. b Relative percentages of Tregs, 
 CD8+ T cells, the effector to suppressor ratio and  CD4+ T cells are 
shown for the expansion cohort. Patients were again treated with 
50 mg CTX once daily, combined with 10 mg everolimus once daily 
as previously in cohort 2. Means ± SEM are shown
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in the expansion cohort first showed a significant decrease 
at week 2, followed by a significant increase at week 4. Fur-
thermore, the increase in Ki-67+ Treg cells at time point 
4 was more abundant and significantly different compared 
to cohort 0. Although an increase in Ki-67 expression in 
 CD4+ T cells was also observed, it failed to reach statistical 
significance.
CTX results in a decrease in the frequency 
of monocytic MDSC
As MDSC are key players in immune suppression in the 
tumor microenvironment as well as systemically, being 
able to contribute to tumor progression and metastasis [18], 
the percentages of monocytic MDSC (mMDSC, defined as 
 Lin−CD14+HLA-DR−) in peripheral blood were determined 
in all cohorts. As shown in Fig. 2a, treatment with everoli-
mus alone resulted in a non-significant increase in mMDSC. 
With the exception of cohort 3, addition of CTX resulted in 
a decrease in the frequency of mMDSC. In cohort 2, this 
decrease relative to levels in cohort 0 reached statistical 
significance (p < 0.01) at time point 4 weeks. In addition, 
within cohort 2, a significant difference between mMDSC 
percentages at baseline versus time point 4 was observed 
(p < 0.05). Although less pronounced, the results of the 
expansion cohort confirmed the earlier observed decrease 
in the frequency of mMDSC, with a significant difference 
between the expansion cohort and cohort 0 at time point 4 
(p < 0.05, Fig. 2b).
Fig. 2  Effect of different 
dosages and administra-
tion schedules of CTX when 
combined with a fixed dose 
of 10 mg everolimus on 
the frequency of mMDSC. 
a Relative percentages of 
mMDSC (to start) defined 
as  Lin−CD14+HLA-DR− are 
shown for the six investigated 
CTX cohorts (black bul-
lets, black line), compared to 
cohort 0 (open bullet, dotted 
line). b Relative percentages 
of mMDSC are shown for the 
expansion cohort. Means ± SEM 
are shown
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Addition of CTX reverses the effects of everolimus 
on blood DC subsets
To assess the effects of the combination of everolimus and 
CTX on blood DC subsets, the percentages and activation 
status of three blood DC subsets were determined, i.e., con-
ventional DC1 (cDC1, defined as  BDCA3+CD14−CD11c+), 
cDC2 (defined as  BDCA1+CD19−CD14−CD11c+), and 
plasmacytoid DC (pDC, defined as  BDCA2+CD123+) [19]. 
The activation status of these subsets was determined by 
MFI measurement of CD86 (and in addition CD40, data 
not shown). In cohort 0, a significant decrease in the fre-
quency of cDC1 at time point 2 and 4 weeks, and of the 
cDC2 subset at time point 2 weeks was noted. Addition of 
CTX diminished these effects (Fig. 3a). Interestingly, an 
actual increase in both cDC1 and cDC2 percentages was 
most pronounced with increasing doses of CTX. Addition 
of CTX to everolimus also resulted in an increase in the 
frequency of pDC, which reached statistical significance at 
week 4 in both cohort 2 and cohort 5. The expansion cohort 
(Fig. 3b) confirmed the changes previously noted in patients 
treated in cohort 2.
Treatment with everolimus alone resulted in a significant 
decrease in the expression of CD86 on the cDC1 and pDC 
subsets, at week 4 and 2, respectively, both with a p ≤ 0.05. 
As shown in Fig. 4a, CTX was capable of reversing this 
downregulation of CD86 expression on cDC1 reaching 
statistical significance in all CTX cohorts except cohort 
3. While CTX did not result in a significant alteration of 
CD86 expression on cDC2, an increase in the expression 
of CD86 on pDC was observed in cohorts 3, 5 and 6 when 
compared to the patient group treated with everolimus alone 
(i.e., cohort 0).
Figure 4b shows the changes in MFI of CD86 on the three 
blood DC subsets in the expansion cohort, again confirming 
the results previously seen in patients treated in cohort 2.
Addition of CTX does not result in enhanced NK cell 
frequencies
A previously published article reported beneficial effects of 
low-dose metronomic CTX on NK cell function [15]. Two 
distinct NK cell subsets were monitored, the immunoregula-
tory  CD56brightCD16dim/− and the cytotoxic  CD56dimCD16+ 
subset. As shown in Fig. 5a, 4 weeks of treatment with 
everolimus alone resulted in a significant reduction in 
 CD56brightCD16dim/− NK cells (Fig. 5a, left panels). Addition 
of CTX resulted in a dose-dependent reversal of this effect 
with higher doses of CTX actually inducing an increase in 
the frequency of immunoregulatory NK cells. While treat-
ment with everolimus resulted in a temporary (non-signif-
icant) increase in the frequency of  CD56dimCD16+ cyto-
toxic NK cells, this effect was attenuated by the addition 
of CTX and actually resulted in a significant decrease in 
 CD56dimCD16+ NK cells in cohorts 4 and 6 with effects 
being most striking in cohort 6. Again, the expansion cohort 
confirmed the earlier observed data in patients treated in 
cohort 2 (Fig. 5b).
Overall effect of the addition of continuous 
once daily oral administration of 50 mg 
of cyclophosphamide on immune cell populations 
in patients with mRCC treated with everolimus
Figure 6 shows the data from patients treated with 10 mg 
once daily everolimus (i.e., cohort 0) versus all patients 
treated with the combination of 10 mg once daily everoli-
mus and 50 mg cyclophosphamide in a continuous scheme 
(i.e., cohort 2 and the expansion cohort, together designated 
“combined cohort 2”). In this combined cohort, a signifi-
cant decrease in Tregs was observed and accompanied by 
an increase in the frequency of  CD8+ T cells. Together, this 
resulted in a significant increase in the  CD8+ T cell:Treg 
ratio (Fig.  6a). Interestingly, the combined cohort also 
showed a significant decrease in Ki-67+ Tregs at week 2, 
followed by a significant increase at week 4 compared to 
week 0. Additionally, a significant difference between the 
combined cohort and cohort 0 was found at week 4. The 
Ki-67 expression in  CD4+ T cells decreased significantly 
at week 2 and although the Ki-67+CD4+ T-cell percentages 
were higher in the combined cohort 2 compared to cohort 0, 
this difference was not significant (Fig. 6b). Notable was also 
the observation that whereas mMDSC frequencies increased 
in patients treated with everolimus alone, the frequency sig-
nificantly decreased in the combined cohort 2 both at time 
point 2 as well as 4 weeks (Fig. 6c) with a significant differ-
ence between the percentages at time point 4 when compar-
ing the combined cohort to cohort 0. The decrease in cDC1 
and cDC2 percentages that was observed with everolimus 
monotherapy was reversed by adding CTX to the treatment, 
with a significant difference when comparing to cohort 0 at 
time point 4 (Fig. 6d). In addition, 50 mg of CTX once daily 
continuously in combination with everolimus resulted in a 
reversal of the effect on the immunoregulatory NK cells, 
however, a decrease in cytotoxic NK cells was observed at 
time point 2 (p < 0.05, Fig. 6e). No significant differences 
between the combined cohort 2 and cohort 0 were observed 
for the T-cell activation markers, although there was a 
Fig. 3  Effect of different dosages and administration schedules of 
CTX when combined with a fixed dose of 10 mg everolimus on the 
frequency of three blood DC subsets. a Relative percentages of cDC1 
 (BDCA3+CD14−CD11c+), cDC2  (BDCA1+CD19−CD14−CD11c+), 
and pDC  (BDCA2+CD123+) are shown for the six investigated CTX 
cohorts (black bullets, black line), compared to cohort 0 (open bul-
let, dotted line), relative to start. b Relative percentages of the three 
subsets are shown for the expansion cohort. Means ± SEM are shown
◂
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notable increase in frequency of  CD4+CTLA-4+ T cells by 
week 4 (Fig. 6f).
Discussion
This is the first clinical trial in which several dosages and 
schedules of metronomic cyclophosphamide in combination 
with the standard dosage of everolimus were investigated, 
and where extensive and comprehensive immune monitoring 
was performed. Our data indicate that while the frequency 
of Tregs slowly increased during treatment with everolimus 
alone, the combination of 10 mg everolimus once daily and 
50 mg CTX once daily continuously, resulted in a signifi-
cant decrease of Tregs within 2 weeks of treatment. This 
decrease persisted up to week 4 returning to baseline levels 
after 8 weeks of combination treatment. The slight increase 
in Treg percentages that was observed at 4 and 8 weeks of 
treatment suggest the reduction in Tregs to be a temporary 
effect, as was previously also reported in advanced-stage 
breast cancer patients treated with single-agent 50 mg CTX 
p.o. daily [20] and which is in line with the observation of an 
increase in the expression of the proliferation marker Ki-67 
in Tregs at time points 4 and 8 weeks. Though this may seem 
to limit the rationale for combination treatment of CTX and 
everolimus, Ge et al. [20] reported that transient depletion 
of Tregs can increase tumor-reactive T-cell numbers imply-
ing that even a temporary Treg depletion may sufficiently 
boost the anti-tumor immune response, by creating a win-
dow for T-cell priming against the tumor. In addition, in the 
combined cohort 2  CD8+ T-cell percentages significantly 
increased and together with the decrease in Treg percent-
ages resulted in an increase in the effector to suppressor ratio 
 (CD8+ T cell:Tregs). Since an increased effector to suppres-
sor ratio is associated with improved survival [21–23], this 
may imply positive effects on the survival of mRCC patients 
when treated with a combination of everolimus and CTX. 
Of note, the mechanism behind these reduced cell amounts, 
e.g., by necrosis or apoptosis, has not been examined.
The combined cohort 2 analysis also revealed a sig-
nificant decrease in the frequency of mMDSC after 2 and 
4 weeks of treatment. As the role of MDSC in the tumor 
environment is diverse [18] leading to promotion of tumor 
growth, this mMDSC-depleting effect, though temporary 
in nature as the decrease in mMDSC did not persist after 
4 weeks of combination treatment, could further contribute 
to improved survival. Of interest, sunitinib has also been 
reported to decrease the frequency of myeloid suppressor 
cells [24]. As lenvatinib is not only a TKI directed against 
the VEGF receptor [25] but additionally inhibits fibroblast 
growth factor receptor (FGFR) which may also dampen 
MDSC activity [26], the combination of lenvatinib and 
everolimus might exert similar or even more pronounced 
effects on the immune system as the combination of everoli-
mus and CTX.
Previously, we reported that treatment with everolimus 
alone significantly reduced the frequency of the cDC1 and 
cDC2 blood DC subsets, while it did not affect the frequency 
of pDC [27]. Interestingly, we here demonstrate that the 
addition of any dosage or scheme of CTX could reverse 
these everolimus-induced alterations in the frequency 
of cDC1 and cDC2. Furthermore, CTX was also able to 
increase the activation of at least two of the three blood DC 
subsets, the cDC1 and pDC subset. While cohort 2 already 
showed beneficial effects on the blood DC subsets, effects 
were even more pronounced when higher doses of CTX were 
used.
As Ghiringhelli et al. [15] reported beneficial effects of 
CTX treatment on NK and T cell effector functions, we were 
interested in the effects of the combination of everolimus 
and CTX on both cell subsets. We found that adding CTX 
to everolimus could reverse the effects of everolimus mono-
therapy on the immunoregulatory  CD56brightCD16dim/− NK 
cell subset as well as on the cytotoxic  CD56dimCD16+ 
NK cell population, overall resulting in an increase in the 
frequency of immunoregulatory NK cells and a decrease 
in the frequency of cytotoxic NK cells with combination 
therapy. For both NK cell subsets, functional analyses were 
not performed, and therefore it remains impossible to deter-
mine whether these subsets are also functionally compro-
mised as previously reported [28]. For both the  CD4+ and 
 CD8+ T cell subset the expression of PD-1 and CTLA-4 
was determined. Though not significant, a minor increase 
in expression of PD-1 and CTLA-4 could be noted, perhaps 
suggesting an increase in tumor-specific effector T cells and 
a window for combination therapy with immune checkpoint 
inhibitors targeting CTLA-4 and/or PD-1 [29].
In conclusion, we performed a phase 1 study in patients 
with mRCC treated with everolimus alone and the combi-
nation of everolimus and different doses and administra-
tion schedules of CTX and here report on the compre-
hensive immunomonitoring that was performed in these 
patients. The predefined goal of the study, i.e., to identify 
the dose and schedule of CTX that when combined with 
everolimus would result in optimal and selective deple-
tion of Tregs, was achieved with a once daily continuous 
oral dose of 50 mg CTX. Addition of this dose of CTX 
to everolimus, resulted in depletion of Tregs, a sustained 
Fig. 4  Effect of different dosages and administration schedules of 
CTX when combined with a fixed dose of 10 mg everolimus on the 
activation status of three blood DC subsets. a Relative MFI of CD86 
was determined for the cDC1, cDC2, and pDC subset and shown for 
the six investigated CTX cohorts (black bullets, black line), compared 
to cohort 0 (open bullet, dotted line). b Relative percentages of the 
MFI of CD86 on cDC1, cDC2, and pDC shown for the expansion 
cohort. Means ± SEM are shown
◂
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Fig. 5  Effect of different dos-
ages and administration sched-
ules of CTX when combined 
with a fixed dose of 10 mg 
everolimus on the frequency of 
NK cells. a Relative percent-
ages of immunoregulatory 
 (CD56brightCD16dim/−) and 
cytotoxic  (CD56dimCD16+) 
NK cells are shown for the six 
investigated CTX cohorts (black 
bullets, black line), compared 
to cohort 0 (open bullet, dotted 
line). b Relative percentages 
of the NK subsets are shown 
for the expansion cohort. 
Means ± SEM are shown
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increase in  CD8+ T cells with an increase in the effector 
to suppressor ratio. Furthermore, this combination therapy 
resulted in a depletion of mMDSC, while negative effects 
of monotherapy with everolimus on blood DC subsets 
were counteracted. All together, these observed changes 
in various immune cell populations may result in increased 
antitumor immunity and improved survival of patients 
with mRCC, which is currently further investigated in a 
phase 2 clinical trial [16].
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Fig. 6  Overview of changes in immune cell subsets in cohort 0 com-
pared to the combined cohort 2 (i.e., cohort 2 and cohort 2E). Patients 
were treated with 50  mg CTX once daily, combined with 10  mg 
everolimus once daily. a Tregs within  CD4+ T cells,  CD8+ T cells 
within  CD3+ T cells and the ratio of  CD8+ T cells versus Tregs are 
shown. b Ki-67 expression in Tregs and  CD4+ T cells. c mMDSC. 
d Blood DC subsets. e NK cell subsets. f PD-1 and CTLA-4 expres-
sion on  CD4+ and  CD8+ T cells. Panels show the combined cohort 2 
(black bullets, black line) versus cohort 0 (open bullet, dotted line). 
Means ± SEM are shown
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